What do systematic reviews say?

Fondaparinux vs heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dalteparin vs tinzaparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs unfractionated heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

Capecitabine‐containing regimens showed no clear difference in febrile neutropenia compared with non‐capecitabine‐containing regimens (moderate certainty).

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  OR 1.31 [0.97, 1.77]
  4 studies · 2890 participants
  Moderate

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  OR 0.55 [0.47, 0.64]
  5 studies · 8086 participants
  Moderate

Summary of findings: Fibrin sealant vs Conventional (simple interrupted) suturing

Fibrin sealant led to higher trismus / maximum mouth opening (mean) compared with conventional suturing; GRADE not reported.

• Surgical techniques for the removal of mandibular wisdom teeth 2020 · Cochrane All outcomes

  7 days · fibrin sealant vs conventional
  MD 3.50 [2.69, 4.31]
  1 study · 30 participants
  GRADE not reported

Lingual nerve retractor (subperiosteal or Free's) vs No retractor

The review found no eligible studies for this question.

• Surgical techniques for the removal of mandibular wisdom teeth 2020 · Cochrane All outcomes

  7 days
  no estimate extracted
  Studies not reported
  No studies found

Drain use vs No drain

Surgical drain (tube or gauze) led to higher maximum mouth opening (mean) compared with no drain; GRADE not reported.

• Surgical techniques for the removal of mandibular wisdom teeth 2020 · Cochrane All outcomes

  7 days
  MD 3.11 [2.20, 4.02]
  4 studies · 234 participants
  GRADE not reported

Mycophenolate mofetil vs levamisole

It is very uncertain whether mycophenolate mofetil changes adverse effects: leukopenia compared with levamisole (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 2.88 [0.12, 69.65]
  1 study · 149 participants
  Very low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.64 [0.08, 4.85]
  2 studies · 84 participants
  Low

Levamisole vs steroids or placebo or both, or no treatment

Levamisole showed no clear difference in adverse effects: leucopenia compared with steroids or placebo or both, or no treatment (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 4.18 [0.72, 24.21]
  3 studies · 214 participants
  Low

Levamisole vs cyclophosphamide

Levamisole showed no clear difference in adverse effects: leucopenia compared with cyclophosphamide (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.25 [0.04, 1.48]
  2 studies · 97 participants
  Low

Alkylating agents vs cyclosporin

It is very uncertain whether alkylating agents changes adverse effects: leucopenia compared with cyclosporin (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 29.84 [1.84, 483.93]
  1 study · 66 participants
  Very low

Alkylating agents vs steroids, placebo or both

Alkylating agents led to higher CPA: leucopenia compared with steroids, placebo or both; GRADE not reported.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 10.63 [1.45, 78.05]
  Studies not reported
  GRADE not reported

Alkylating agents vs steroids, placebo or both

Alkylating agents showed no clear difference in chlorambucil: leucopenia compared with steroids, placebo or both; GRADE not reported.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 2.5 [0.11, 54.87]
  Studies not reported
  GRADE not reported

Intravenous vs oral cyclophosphamide

Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.37 [0.09, 1.51]
  2 studies · 83 participants
  Low

Cyclophosphamide vs chlorambucil

Cyclophosphamide may leads to lower adverse effects: lymphopenia compared with chlorambucil (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.43 [0.21, 0.87]
  1 study · 50 participants
  Low

Cyclophosphamide vs chlorambucil

Cyclophosphamide may leads to lower adverse effects: thrombocytopenia compared with chlorambucil (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.43 [0.21, 0.87]
  1 study · 50 participants
  Low

Intervention not reported

• Interventions to slow progression of myopia in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Moderate

Carboplatin vs cisplatin chemotherapy

Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).

• Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
  RR 2.46 [1.49, 4.04]
  10 studies · 3857 participants
  Moderate